BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MDNA11 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MDNA11\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05086692-2616@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:MDNA11: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:MDNA11\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Beta
 -only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 October 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mdna11#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05086692
URL:https://assetmemo.bio/drug/mdna11#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
